Aimovig price aligns with clinical benefit for migraine patients who have exhausted other options, says ICER

The USA’s Institute for Clinical and Economic Review has released an  Evidence Report assessing the comparative clinical effectiveness and value of three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine attacks.

The health technology assessor notes that the drugs in question as Amgen (Nasdaq: AMGN) and Novartis’ (NOVN: VX) Aimovig (erenumab), fremanezumab, from Teva Pharmaceutical Industries (NYSE: TEVA), and galcanezumab from Eli Lilly (NYSE: LLY).

Erenumab was approved by the US Food and Drug Administration earlier this month. Most analysts expect the drug to achieve blockbuster status, with peak sales forecast to come in at between $1 billion and $2 billion. The other two agents remain under FDA review.